| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962572 | FRESENIUS KABI USA | Bortezomib formulations |
Nov, 2032
(9 years from now) | |
Bortezomib is owned by Fresenius Kabi Usa.
Bortezomib contains Bortezomib.
Bortezomib has a total of 1 drug patent out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 06 November, 2017.
Bortezomib is available in powder;intravenous dosage forms.
The generics of Bortezomib are possible to be released after 03 November, 2032.
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 06 November, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BORTEZOMIB family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(19 years from now) | |
Bortezomib is owned by Maia Pharms Inc.
Bortezomib contains Bortezomib.
Bortezomib has a total of 1 drug patent out of which 0 drug patents have expired.
Bortezomib was authorised for market use on 27 July, 2022.
Bortezomib is available in solution;intravenous dosage forms.
Bortezomib can be used as treatment of adult patients with multiple myeloma; treatment of adult patients with mantle cell lymphoma.
The generics of Bortezomib are possible to be released after 23 September, 2042.
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma; Treatment of adult patients with mantle cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
BORTEZOMIB family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic